The present disclosure relates to complexes comprising caffeine and tannic acid as well as emulsions and beverages comprising these complexes which slow the release of the caffeine. Also described are methods of preparing the complexes and emulsions and beverages comprising caffeine-tannic acid complexes.

The present disclosure relates to complexes comprising caffeine and tannic acid as well as emulsions and beverages comprising these complexes which slow the release of the caffeine. Also described are methods of preparing the complexes and emulsions and beverages comprising caffeine-tannic acid complexes.

The present disclosure features a luminescent molecule, including a luminophore (e.g., a fluorescent dye); and a moiety including a heteroaryl core covalently and directly bonded to the luminophore. The luminescent molecule has an increased photoluminescence quantum yield relative to an analogous luminophore without a covalently bonded moiety including the heteroaryl core.

The present disclosure features a luminescent molecule, including a luminophore (e.g., a fluorescent dye); and a moiety including a heteroaryl core covalently and directly bonded to the luminophore. The luminescent molecule has an increased photoluminescence quantum yield relative to an analogous luminophore without a covalently bonded moiety including the heteroaryl core.

Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha-synuclein is implicated, including Parkinson's disease. Methods of making and using the bifunctional molecules are disclosed.

Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha-synuclein is implicated, including Parkinson's disease. Methods of making and using the bifunctional molecules are disclosed.

The present invention provides an enzymatic means for the biosynthetic production of caffeine. The present invention provides biosynthetic methods for production of caffeine comprising: providing guanine, a guanine deaminase, at least one methyl transferase, and a methyl donor; contacting the guanine with the gtheuanine deaminase to produce xanthine; contacting the xanthine with the methyl transferase and a methyl donor, under conditions wherein the xanthine is methylated, to produce a monomethylxanthine; contacting the monomethylxanthine with the methyl transferase and a methyl donor, under conditions wherein the monomethylxanthine is methylated, to produce a dimethylxanthine; and contacting the dimethylxanthine with the methyl transferase and a methyl donor, under conditions wherein the dimethylxanthine is methylated, to produce caffeine (i.e., 1,3,7-trimethylxanthine).

New tetrahydrocannabinolic acid cocrystals are disclosed, in particular, a 1:1 tetrahydrocannabinolic acid L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D,L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid ethyl maltol cocrystal and a 1:1 tetrahydrocannabinolic acid caffeine cocrystal. The invention also relates to pharaceutical compositions containing a tetrahydrocannabinolic acid cocrystal of the invention and a pharmaceutically acceptable carrier and methods to treat a disease, disorder or condition by administering to a patient in need thereof a therapeutically effective amount of tetrahydrocannabinolic acid cocrystal or a pharmaceutical composition containing a tetrahydrocannabinolic acid cocrystal.

New tetrahydrocannabinolic acid cocrystals are disclosed, in particular, a 1:1 tetrahydrocannabinolic acid L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D,L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid ethyl maltol cocrystal and a 1:1 tetrahydrocannabinolic acid caffeine cocrystal. The invention also relates to pharaceutical compositions containing a tetrahydrocannabinolic acid cocrystal of the invention and a pharmaceutically acceptable carrier and methods to treat a disease, disorder or condition by administering to a patient in need thereof a therapeutically effective amount of tetrahydrocannabinolic acid cocrystal or a pharmaceutical composition containing a tetrahydrocannabinolic acid cocrystal.

The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.